Meet DeepLook Medical
Value Proposition
DeepLook Medical’s flagship product, DL Precise™, is an innovative AI-powered software that equips healthcare professionals with the tools to accurately detect and assess suspicious lesions in dense breast tissue. By utilizing cutting-edge algorithms and shape-recognition technology, DL Precise™ delivers unmatched precision in visualizing, measuring, and segmenting abnormal growths. This breakthrough has the potential to significantly improve early cancer detection, ultimately enhancing patient outcomes.
Marissa Fayer
CEO
About
DeepLook Medical focuses on visual enhancement technology to advance medical imaging. DL Precise™ is the first in a series of innovative products using the company’s unique shape-recognition software to delineate the details of tumor morphology – a key to better diagnosis and treatment of malignancy across the field of oncology. The company is leveraging other complementary AI advances to further the reach and impact of its patented technology.
Why We Invested
Investing in DeepLook Medical offers a chance to support a company revolutionizing medical diagnostics, particularly in breast cancer detection, with technology that enhances accuracy and patient outcomes. Their strategic partnership with BARCO strengthens their market position, providing a competitive edge. Additionally, we believe DeepLook Medical has a well-defined exit strategy.
Highlights
DeepLook Medical has secured a significant partnership with BARCO, a renowned global leader in medical monitors. This strategic alliance will accelerate the market penetration and distribution of DeepLook Medicals’s innovative technology.
To support a successful market launch, DeepLook Medical has obtained regulatory approvals in the United States, the United Kingdom, and Canada, with additional clearances pending in Mexico and Israel. The company has also secured intellectual property protection to safeguard its valuable technology and maintain a competitive edge.
Lastly, in a recent study involving six radiologists, DL Precise™ demonstrated its effectiveness in improving diagnostic accuracy. The technology led to a 12% increase in recall rates, helping to align performance with national standards. By providing real-time decision support, DL Precise™ has the potential to reduce unnecessary callbacks and missed cancer cases, ultimately improving patient outcomes.